Beneficial effect of tocilizumab in myasthenia gravis refractory to rituximab

Neuromuscular Disorders

Volumn 27, Issue 6, 2017, Pages 565-568

  Jonsson, Dagur Ingi ^a   Pirskanen, Ritva ^a,b   Piehl, Fredrik ^a,b  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^b KAROLINSKA INSTITUTE   (Sweden)

Author keywords

Immunomodulatory therapy; Myasthenia gravis; Rituximab; Tocilizumab

Indexed keywords

CHOLINERGIC RECEPTOR ANTIBODY; CORTICOSTEROID; CYCLOSPORIN; IMMUNOGLOBULIN; IMMUNOSUPPRESSIVE AGENT; INTERLEUKIN 6; MYCOPHENOLATE MOFETIL; PREDNISOLONE; PYRIDOSTIGMINE; RITUXIMAB; TOCILIZUMAB; ANTIBODY; CHOLINERGIC RECEPTOR; IL6 PROTEIN, HUMAN; IMMUNOLOGIC FACTOR; MONOCLONAL ANTIBODY;

ABSENCE OF SIDE EFFECTS; ADULT; AGED; ANTIBODY TITER; ARTICLE; CASE REPORT; DIZZINESS; DRUG MEGADOSE; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FEMALE; HUMAN; INHIBITION KINETICS; KIDNEY DISEASE; LOW DRUG DOSE; MEDICAL DECISION MAKING; MYASTHENIA GRAVIS; NERVE STIMULATION; PANCREAS DISEASE; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; SINGLE DRUG DOSE; THYMECTOMY; TREATMENT OUTCOME; TREATMENT RESPONSE; VERY ELDERLY; YOUNG ADULT; ANTAGONISTS AND INHIBITORS; BLOOD; COMPLICATION; IMMUNOLOGY; MUSCLE FATIGUE;

ADULT; AGED, 80 AND OVER; ANTIBODIES; ANTIBODIES, MONOCLONAL, HUMANIZED; FEMALE; HUMANS; IMMUNOLOGIC FACTORS; INTERLEUKIN-6; MUSCLE FATIGUE; MYASTHENIA GRAVIS; RECEPTORS, CHOLINERGIC; RITUXIMAB; TREATMENT OUTCOME; YOUNG ADULT;

EID: 85017514346     PISSN: 09608966     EISSN: 18732364     Source Type: Journal    
DOI: 10.1016/j.nmd.2017.03.007     Document Type: Article

References (20)

1. Vincent, A., Palace, J., Hilton-Jones, D., Myasthenia gravis. Lancet 357 (2001), 2122–2128.
2. Meriggioli, M.N., Sanders, D.B., Autoimmune myasthenia gravis: emerging clinical and biological heterogeneity. Lancet Neurol 8 (2009), 475–490.
3. Sanders, D.B., Wolfe, G.I., Benatar, M., et al. International consensus guidance for management of myasthenia gravis: executive summary. Neurology 87 (2016), 419–425.
4. Howard, J.F. Jr, Barohn, R.J., Cutter, G.R., et al. A randomized, double-blind, placebo-controlled phase II study of eculizumab in patients with refractory generalized myasthenia gravis. Muscle Nerve 48 (2013), 76–84.
5. Iorio, R., Damato, V., Alboini, P.E., Evoli, A., Efficacy and safety of rituximab for myasthenia gravis: a systematic review and meta-analysis. J Neurol 262 (2015), 1115–1119.
6. Teitsma, X.M., Marijnissen, A.K., Bijlsma, J.W., Lafeber, F.P., Jacobs, J.W., Tocilizumab as monotherapy or combination therapy for treating active rheumatoid arthritis: a meta-analysis of efficacy and safety reported in randomized controlled trials. Arthritis Res Ther, 18, 2016, 211.
7. Chihara, N., Aranami, T., Sato, W., et al. Interleukin 6 signaling promotes anti-aquaporin 4 autoantibody production from plasmablasts in neuromyelitis optica. Proc Natl Acad Sci USA 108 (2011), 3701–3706.
8. Araki, M., Matsuoka, T., Miyamoto, K., et al. Efficacy of the anti-IL-6 receptor antibody tocilizumab in neuromyelitis optica: a pilot study. Neurology 82 (2014), 1302–1306.
9. Ayzenberg, I., Kleiter, I., Schroder, A., et al. Interleukin 6 receptor blockade in patients with neuromyelitis optica nonresponsive to anti-CD20 therapy. JAMA Neurol 70 (2013), 394–397.
10. Bedlack, R.S., Simel, D.L., Bosworth, H., Samsa, G., Tucker-Lipscomb, B., Sanders, D.B., Quantitative myasthenia gravis score: assessment of responsiveness and longitudinal validity. Neurology 64 (2005), 1968–1970.
11. Li, R., Rezk, A., Miyazaki, Y., et al. Proinflammatory GM-CSF-producing B cells in multiple sclerosis and B cell depletion therapy. Sci Transl Med, 7, 2015, 310ra166.
12. Molnarfi, N., Schulze-Topphoff, U., Weber, M.S., et al. MHC class II-dependent B cell APC function is required for induction of CNS autoimmunity independent of myelin-specific antibodies. J Exp Med 210 (2013), 2921–2937.
13. Barr, T.A., Shen, P., Brown, S., et al. B cell depletion therapy ameliorates autoimmune disease through ablation of IL-6-producing B cells. J Exp Med 209 (2012), 1001–1010.
14. Kremer, J.M., Blanco, R., Halland, A.M., et al. Clinical efficacy and safety maintained up to 5 years in patients with rheumatoid arthritis treated with tocilizumab in a randomised trial. Clin Exp Rheumatol 34 (2016), 625–633.
15. Iking-Konert, C., Von Hinuber, U., Richter, C., et al. ROUTINE-a prospective, multicentre, non-interventional, observational study to evaluate the safety and effectiveness of intravenous tocilizumab for the treatment of active rheumatoid arthritis in daily practice in Germany. Rheumatology (Oxford) 55 (2016), 624–635.
16. Yamamoto, K, Goto, H., Hirao, K., et al. Long term safety of tocilizumab: results from 3 years of followup postmarketing surveillance of 5573 patients with rheumatoid arthritis in Japan. J Rheumatol 42 (2015), 1368–1375.
17. Bijlsma, J.W., Welsing, P.M., Woodworth, T.G., et al. Early rheumatoid arthritis treated with tocilizumab, methotrexate, or their combination (U-Act-Early): a multicentre, randomised, double-blind, double-dummy, strategy trial. Lancet 388 (2016), 343–355.
18. Kojima, T., Yabe, Y., Kaneko, A., et al. Monitoring C-reactive protein levels to predict favourable clinical outcomes from tocilizumab treatment in patients with rheumatoid arthritis. Mod Rheumatol 23 (2013), 977–985.
19. Nielsen, A.S., Miravalle, A., Langer-Gould, A., Cooper, J., Edwards, K.R., Kinkel, R.P., Maximally tolerated versus minimally effective dose: the case of rituximab in multiple sclerosis. Mult Scler 18 (2012), 377–378.
20. Salzer, J., Svenningsson, R., Alping, P., et al. Rituximab in multiple sclerosis: a retrospective observational study on safety and efficacy. Neurology 87 (2016), 2074–2081.